A clearer reading
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Registry metadata, preparation and research links; registration is not proof of benefit.
Registration describes a study. It does not establish benefit, retail product efficacy, vendor quality or current recruitment availability.
The registry record was last updated more than a year before our check. Its sponsor-reported status may be out of date; follow the original record for current information.
NCT02091375 · CBD
- Registry status
- Completed — sponsor-reported
- Phase
- Phase 3
- Registry results
- Results tables posted in registry
- Study preparation
- GWP42003-P purified CBD oral solution, compared with matched placebo alongside existing treatment.
- Population
- Children and young adults with Dravet syndrome.
- Registered enrollment
- 120 (actual)
- Lead sponsor
- Jazz Pharmaceuticals
- First posted
- 2014-03-19
- Registry last update posted
- 2022-09-28
- Sponsor status verified
- 2022-09
- Our source check
- 2026-10-25
Interpretation limit
A specific investigational/prescription-style preparation and patient population; not evidence for retail CBD equivalence.
Read the related research in context.
Related paper coverage is separate from registry-posted results tables.
Related primary paperSuggest a source correction
Copy a note and share it with the person who sent this preview. This page does not send or store your note.